BESINS Healthcare Australia and Arrotex Pharmaceuticals have announced a new strategic partnership that sees Arrotex representing the menopausal hormone therapy Prometrium (micronised progesterone) to pharmacies.
The partnership aligns Besins' global expertise in hormone therapies with Arrotex's local capability in patient access, pharmacy engagement and supply confidence.
Under the agreement, Arrotex has also been granted an exclusive license for an authorised generic, expected to be available in quarter two 2026, and says it hopes to get PBS listing shortly after.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Apr 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Apr 26
